Deep Track Biotechnology Master Fund, Ltd.
CIK: 0002015536
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (10 total)
- Aug 6, 2026ATTO
Attovia Therapeutics, Inc.
Conversion(C)Direct2M shares- - Jul 30, 2026LBRX
LB PHARMACEUTICALS INC
Purchase(P)DirectPre-Funded Warrants (Right to Buy)
286.2K shares at avg. $34.94- - Feb 10, 2026DVAX
DYNAVAX TECHNOLOGIES CORP
Tender Offer(U)Direct15.7M shares- - Feb 6, 2026LBRX
LB PHARMACEUTICALS INC
Purchase(P)IndirectPre-Funded Warrants (Right to Buy)
93.9K shares at avg. $21.17- - Feb 6, 2026LBRX
LB PHARMACEUTICALS INC
Purchase(P)DirectPre-Funded Warrants (Right to Buy)
378.4K shares at avg. $21.17- - Sep 12, 2025LBRX
LB PHARMACEUTICALS INC
Purchase(P)Indirect666.7K shares at avg. $15.00$10.0M - Sep 12, 2025LBRX
LB PHARMACEUTICALS INC
Conversion(C)Direct686.1K shares- - Sep 12, 2025LBRX
LB PHARMACEUTICALS INC
Purchase(P)Direct2M shares at avg. $15.00$30.0M - Aug 22, 2025DVAX
DYNAVAX TECHNOLOGIES CORP
Sale(S)Direct970.1K shares at avg. $10.59$10.3M - Aug 21, 2025DVAX
DYNAVAX TECHNOLOGIES CORP
Sale(S)Direct1.1M shares at avg. $11.03$12.1M
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 6, 2026 |  ATTO Attovia Therapeutics, Inc. | Conversion(C) | 1,957,138 | - | $0 | Direct |
| Jul 30, 2026 |  LBRX LB PHARMACEUTICALS INC | Purchase(P) Pre-Funded Warrants (Right to Buy) | 286,205 | $34.94 | - | Direct |
| Feb 10, 2026 |  DVAX DYNAVAX TECHNOLOGIES CORP | Tender Offer(U) | 15,726,349 | - | $0 | Direct |
| Feb 6, 2026 | LBRX LB PHARMACEUTICALS INC | Purchase(P) Pre-Funded Warrants (Right to Buy) | 93,925 | $21.17 | - | Indirect |
| Feb 6, 2026 | LBRX LB PHARMACEUTICALS INC | Purchase(P) Pre-Funded Warrants (Right to Buy) | 378,444 | $21.17 | - | Direct |
| Sep 12, 2025 | LBRX LB PHARMACEUTICALS INC | Purchase(P) | 666,666 | $15.00 | $9,999,990 | Indirect |
| Sep 12, 2025 | LBRX LB PHARMACEUTICALS INC | Conversion(C) | 686,138 | - | - | Direct |
| Sep 12, 2025 | LBRX LB PHARMACEUTICALS INC | Purchase(P) | 2,000,000 | $15.00 | $30,000,000 | Direct |
| Aug 22, 2025 | DVAX DYNAVAX TECHNOLOGIES CORP | Sale(S) | 970,143 | $10.59 | $10,273,814 | Direct |
| Aug 21, 2025 | DVAX DYNAVAX TECHNOLOGIES CORP | Sale(S) | 1,094,994 | $11.03 | $12,077,784 | Direct |
1-10 of 10 transactions
About Deep Track Biotechnology Master Fund, Ltd.
Deep Track Biotechnology Master Fund, Ltd. (SEC CIK 0002015536) files insider reports with the SEC as 10% Owner of Attovia Therapeutics, Inc. (ATTO), 10% Owner of LB PHARMACEUTICALS INC (LBRX) and 10% Owner of DYNAVAX TECHNOLOGIES CORP (DVAX).
Signal8 holds 9 ownership filings by Deep Track Biotechnology Master Fund, Ltd. (3 Form 3, 6 Form 4), filed between Oct 24, 2024 and Aug 10, 2026. Those filings report 10 transactions, from Aug 21, 2025 to Aug 6, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Deep Track Biotechnology Master Fund, Ltd.'s filings is in GEORGE TOWN.
Recent filings by Deep Track Biotechnology Master Fund, Ltd.
- Aug 6, 2026: Conversion of ATTO shares (Form 4, code C).
- Jul 30, 2026: Open-market purchase of LBRX derivative securities (Form 4, code P).
- Feb 10, 2026: Tender of shares transaction of DVAX shares (Form 4, code U).
- Feb 6, 2026: Open-market purchases of LBRX derivative securities (2 lines, Form 4, code P).
- Sep 12, 2025: Open-market purchase of LBRX shares (Form 4, code P).
Other insiders filing for Attovia Therapeutics, Inc. (ATTO)
- Fu Tao, President and CEO
- Chan Steven, Chief Financial Officer
- WALSH COLIN, Director
- GOLDMAN SACHS GROUP INC, Officer
- venBio Global Strategic Fund IV, L.P., 10% Owner
- Redmile Group, LLC, 10% Owner